Choroidal Structural Changes in Myopic Choroidal Neovascularization After Treatment With Antivascular Endothelial Growth Factor Over 1 Year
Choroidal Structural Changes in Myopic Choroidal Neovascularization After Treatment With Antivascular Endothelial Growth Factor Over 1 Year
复制标题
DOI：
10.1167/iovs.16-20191
复制
发表时间：
2016-09-01
影响因子：
4.4
通讯作者：
Cheung, Gemmy Chui Ming
中科院分区：
文献类型：
--
作者：
Wei Yan Ng;Ting, Daniel Shu Wei;Cheung, Gemmy Chui Ming
PUROSE。评估接受抗VEGF治疗12个月以上的近视性脉络膜新生血管（mCNV）患者的脉络膜结构变化。方法。我们采用光谱域光学相干断层扫描（SD-OCT）前瞻性评估了单侧mCNV患者双眼基线、6个月和12个月时的中心凹下脉络膜厚度（SFCT）和脉络膜血管指数（CVI）。脉络膜血管指数定义为SD-OCT图像数字化后管腔面积与脉络膜总面积的比值。我们纳入了20例患者（20只眼mCNV，20只眼无mCNV），平均年龄为60.35 ± 10.85岁。基线时，mCNV患眼和对侧患眼的平均SFCT和CVI相似（SFCT为69.20 +/- 63.04 μ m vs. 67.10 +/- 65.74 μ m，P = 0.713; CVI为59.44 +/- 3.92% vs. 59.03 +/-5.58%，P = 0.958）。在抗VEGF治疗后12个月，mCNV眼的中心凹下脉络膜厚度显著降低至54.75 +/- 45.43 μ m（P = 0.017），而对侧眼的SFCT没有显著变化。从基线至12个月，mCNV眼或对侧眼的CVI无显著变化。SFCT变薄不影响最终BCVA。在接受抗VEGF治疗超过12个月的mCNV眼中，观察到中心凹下脉络膜变薄，而CVI无变化。这一发现可以用响应于地球仪膨胀的机械拉伸来解释。
PUROSE. To evaluate choroidal structural changes in eyes with myopic choroidal neovascularization (mCNV) treated with anti-VEGF over 12 months.METODS. We prospectively evaluated subfoveal choroidal thickness (SFCT) and choroidal vascularity index (CVI) using spectral-domain optical coherence tomography (SD-OCT) at baseline, 6, and 12 months in both eyes in patients presenting with unilateral mCNV. Choroidal vascularity index was defined as the ratio of luminal area to total choroidal area after SD-OCT images were binarized digitally.RESUILTS. We included 20 patients (20 eyes with mCNV and 20 fellow eyes without mCNV) with mean age of 60.35 +/- 10.85 years. At baseline, mean SFCT and CVI was similar between eyes with mCNV and fellow eyes (69.20 +/- 63.04 mu m vs. 67.10 +/- 65.74 mu m, P = 0.713 for SFCT and 59.44 +/- 3.92% vs. 59.03 +/- 5.58%, P = 0.958 for CVI). Subfoveal choroidal thickness decreased significantly in the mCNV eyes to 54.75 +/- 45.43 mu m (P = 0.017) at 12 months after anti-VEGF therapy, whereas SFCT in the contralateral eyes did not change significantly. There was no significant change in CVI in mCNV eyes or contralateral eyes from baseline to 12 months. Thinning of SFCT did not influence final BCVA.CONCLUSIONS. Thinning of subfoveal choroid without alteration in CVI was observed in eyes with mCNV treated with anti-VEGF therapy over 12 months. This finding may be explained by mechanical stretching in response to globe expansion.